Abstract: Facilitating secure and updated user profile information within a distributed network for facial recognition-based access control systems is disclosed. A user's signature (e.g., facial profile data) is routinely and consistently updated across the access control platform. A remote computing system maintains timely and accurate signature data between user devices and access control devices such that each device benefits from the most updated user information, facial recognition models, and spoof detection models. A user may enroll or disenroll in the access control platform via his or her own mobile device, a cloud-based server, and/or the access control device. The enrollment or disenrollment data may be automatically synchronized and updated throughout the platform. These and other benefits may improve the ease with which users and access controllers (e.g., building owners, landlords, etc.

Abstract: Provided are systems, methods, and apparatuses for entangled threads. In one or more examples, the systems, devices, and methods include generating, via a host, a first thread of a process; generating, via the first thread, a second thread, the first thread configuring the second thread as a proxy of the first thread; and executing the second thread on an accelerator. In some examples, the first thread places itself in the sleep state while the second thread executes on the accelerator. In some examples, the systems, devices, and methods include configuring, via the host, the first thread to execute on a processor of the host, and configuring, via the first thread, the second thread to execute on the accelerator.

Abstract: Systems and methods for providing a dynamic medical practice queueing platform via at least one patient user mobile device in operable connection with a network. An application server is in operable communication with the network to host an application program for displaying, via a display module, a virtual patient queue. The application program includes a user interface module for providing access to the virtual patient queue through the display module. A geofencing module determines the location of a user in reference to a geofenced location. A virtual patient queue module determines a time of arrival of a patient using the current location of the patient and positions the patient within a virtual queue.

Abstract: An ultra-high performance concrete (UHPC) with waste brick powder and preparation method and application thereof are provided, which relates to the technical field of concrete. The preparation method includes the following steps: stimulating activity of a brick powder by a method of mechanically stimulating activity to obtain waste brick powder; and preparing UHPC according to a mass ratio of cement to waste brick powder of 5:5-7:3 to obtain the UHPC with waste brick powder. The UHPC is prepared by treating waste bricks from construction waste (mechanically stimulating activity) to make waste brick powder with activity, therefore partially replacing cement. The UHPC is applied in a construction field.

Abstract: An ultra-high performance concrete (UHPC) with waste brick powder and preparation method and application thereof are provided, which relates to the technical field of concrete. The preparation method includes the following steps: stimulating activity of a brick powder by a method of mechanically stimulating activity to obtain waste brick powder; and preparing UHPC according to a mass ratio of cement to waste brick powder of 5:5-7:3 to obtain the UHPC with waste brick powder. The UHPC is prepared by treating waste bricks from construction waste (mechanically stimulating activity) to make waste brick powder with activity, therefore partially replacing cement. The UHPC is applied in a construction field.

Abstract: Facilitating secure and updated user profile information within a distributed network for facial recognition-based access control systems is disclosed. A user's signature (e.g., facial profile data) is routinely and consistently updated across the access control platform. A remote computing system maintains timely and accurate signature data between user devices and access control devices such that each device benefits from the most updated user information, facial recognition models, and spoof detection models. A user may enroll or disenroll in the access control platform via his or her own mobile device, a cloud-based server, and/or the access control device. The enrollment or disenrollment data may be automatically synchronized and updated throughout the platform. These and other benefits may improve the ease with which users and access controllers (e.g., building owners, landlords, etc.

Abstract: Methods and system are described herein for a media guidance application, which allows a user to more quickly and easily navigate available media listings. Specifically, the media guidance application generates a plurality of media cells each corresponding to a particular media listing. In addition, the media guidance application generates a plurality of presentation criterion cells. Upon selection of a particular presentation criterion cell, the media guidance application reveals media cells that are associated with the particular criterion and conceals media listings that are not associated with the particular criterion.

Abstract: In one aspect, the invention includes an aqueous composition for coating articles including isocyanate resins. The coating composition includes from about 50% to about 100% by weight of at least one thermoplastic acrylic polymer; from about 0.1% to about 20% by weight titanium dioxide; and water. The composition has a basic pH, a solids ratio of from about 58% to about 69% by weight, and is substantially free of quartz pigments.

Abstract: Systems and methods for saving information related to selected media content are provided. The user may select a particular media item (e.g., a television program) and view information associated with the selected media. In response to a user request to save or bookmark the information associated with the media for future retrieval, the interactive media guidance application may save the viewed information (e.g., set a flag or setting to prevent the information from being deleted from a source). The user may later view listings of bookmarked information, select a listing, and display again the saved information. In some embodiments, the user may direct the interactive media guidance application to perform an interactive media guidance application operation (e.g., view, record, reminder or purchase) on a program related to the saved information or on a listing of bookmarked information (e.g., move, delete, copy, or set priority).

Abstract: The invention concerns safe non-interacting drug combinations of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, which is (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (the Agent) and a drug which is either an inducer, inhibitor or a substrate of cytochrome P450, in particular cytochrome P450 isoenzyme 3A4. Particular combinations are useful in treating hyperlipidaemia in humans who are receiving immunosuppressive chemotherapy. A preferred combination is the Agent and a fibrate drug, the use of such a combination in treating hyperlipidaemia in mammals, and medicaments containing such a combination for use in such treatments.

Abstract: The invention concerns safe non-interacting drug combinations of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, which is (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (the Agent) and a drug which is either an inducer, inhibitor or a substrate of cytochrome P450, in particular cytochrome P450 isoenzyme 3A4. Particular combinations are useful in treating hyperlipidaemia in humans who are receiving immunosuppressive chemotherapy. A preferred combination is the Agent and a fibrate drug, the use of such a combination in treating hyperlipidaemia in mammals, and medicaments containing such a combination for use in such treatments.

Abstract: The invention concerns safe non-interacting drug combinations of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, which is (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5 -dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof (the Agent) and a drug which is either an inducer, inhibitor or a substrate of cytochrome P450, in particular cytochrome P450 isoenzyme 3A4. Particular combinations are useful in treating hyperlipidaemia in humans who are receiving immunosuppressive chemotherapy. A preferred combination is the Agent and a fibrate drug, the use of such a combination in treating hyperlipidaemia in mammals, and medicaments containing such a combination for use in such treatments.

Abstract: The invention provides a method for the treatment of heterozygous familial hypercholesterolemia by administering the compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides a method for the treatment of heterozygous familial hypercholesterolemia by administering the compound (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-hept-6-enoic acid or a pharmaceutically acceptable salt thereof.